The benzyl alcohol inhibits bacterial growth upon repeated vial access, allowing the solution to be used across multiple reconstitutions or multiple aliquots from a single vial without contamination risk
Tolerability is not efficacy: A compound can be well tolerated and still fail to work larazotides core limitation is not a safety scare but that the pivotal trial did not show it helped patients [6]
At minimum: Outcomes Weight trend (weekly average) Waist circumference Body composition if available (DEXA, BIA with consistency) Strength markers (basic lifts, grip strength, functional tests) Safety Blood pressure + resting HR A1c and fasting glucose (more often if diabetes) CMP (liver/kidney) Lipids (periodic) If manipulating GH/IGF-1 signaling: IGF-1 (and clinical context matters) Stop criteria Persistent tachycardia, edema, severe fatigue, worsening glycemia, abnormal labs, or new symptoms you cant explain The what to ask your clinic questions (high signal, low fluff) If a clinic recommends a peptide stack, ask: What is the problem were solving, in one sentence
Double the strength of the previous B12
